Drugs / MenACWY-CRM197
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01782066 | Jan 2013 → Feb 2014 | meningococcal infection | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00601731 | Feb 2008 → Jul 2010 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00806195 | Dec 2008 → Mar 2011 | meningitis, meningococcal infection | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00667602 | Mar 2008 → Jul 2009 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACWY-CRM197 | “Different fractional doses of two quadrivalent meningococcal conjugate vaccines (MenACWY-CRM197 (Menveo®) and MenACWY-TT (Nimenrix®)) were administered intradermally to...” PMID 29778515 ↗ May 2018 |
| Modality | Vaccine | “MenACWY conjugate vaccine” NCT00667602 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT00667602 ↗ |